Forxiga® - HFpEF
10mg | Tablets
TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped.
From July 1st 2023 onwards, Forxiga® (dapagliflozin) 10 mg for symptomatic chronic heart failure is fully reimbursement by the health insurer. Therefore the TerugBetaalRegeling (TBR) Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped. The manufacturer of this medicine has reimbursed the costs of the personal contribution to the patient from February 13th until June 30th 2023.
For a complete reimbursement overview of Forxiga® (dapagliflozin) 10 mg, click here
For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.
Dose | Forxiga® 10mg |
Type | Tablets |
Active ingredient | DAPAGLIFLOZINE |
Declaration with an issue date between the above dates can still be submitted until November 1st 2023.
Declaration with an issue date between the above dates can still be submitted until November 1st 2023.
Patients and pharamcists can claim online and will receive the reimbursement within 5 working days.
Patients can claim by post and will receive their reimbursement within 15 working days.
Please mail the Claim Form and attachments to:
TBR Nederland
Postbus 8011
1180 LA Amstelveen
If you need any assistance please read our Frequently Asked Questions.
Still does not work? Please contact our Servicedesk via e-mail or call the Forxiga® service-number 088 - 0026740
Quickly check the maximum contribution you have to pay for your medicine